MeSH keywords -> Related genes, diseases (OMIM)
Query MeSH keywords list
01
Drug Hypersensitivity
[NCBI]
Gene
Gene
Link
Information
Gain
01
HLA-B
[NCBI]
0.000118356
PTGS2
[NCBI]
0.000108116
CYSLTR1
[NCBI]
5.20829e-05
PTGS1
[NCBI]
5.01497e-05
CYP2C9
[NCBI]
3.07244e-05
CTAGE1
[NCBI]
2.82281e-05
XPNPEP2
[NCBI]
2.75625e-05
ENPP3
[NCBI]
2.70641e-05
LTC4S
[NCBI]
2.69081e-05
FCER1A
[NCBI]
2.67568e-05
VKORC1
[NCBI]
2.16923e-05
IFNG
[NCBI]
2.02285e-05
IL4
[NCBI]
2.01234e-05
NAT2
[NCBI]
1.96493e-05
HLA-DRB1
[NCBI]
1.96405e-05
TBXA2R
[NCBI]
1.86674e-05
IL4R
[NCBI]
1.8656e-05
IL13
[NCBI]
1.82467e-05
HSPA1L
[NCBI]
1.69156e-05
SMEK1
[NCBI]
1.48147e-05
CCT2
[NCBI]
1.48147e-05
TIPRL
[NCBI]
1.48147e-05
CYP2C8
[NCBI]
1.44873e-05
HSPA1A
[NCBI]
1.38741e-05
CYSLTR2
[NCBI]
1.24772e-05
CCT4
[NCBI]
1.24345e-05
CCT7
[NCBI]
1.24345e-05
SMEK2
[NCBI]
1.24345e-05
PPP4R1
[NCBI]
1.24345e-05
PPP4R2
[NCBI]
1.24345e-05
LACTB
[NCBI]
1.15363e-05
PPP6C
[NCBI]
1.15363e-05
EPHX1
[NCBI]
1.12268e-05
CCT6A
[NCBI]
1.09531e-05
STAT6
[NCBI]
1.07146e-05
PPP4C
[NCBI]
1.05195e-05
SLC35A1
[NCBI]
1.05195e-05
CCT3
[NCBI]
1.05195e-05
IGBP1
[NCBI]
1.05195e-05
PPP2CB
[NCBI]
1.01741e-05
DCLRE1A
[NCBI]
1.01741e-05
TFDP2
[NCBI]
1.01741e-05
CCT8
[NCBI]
1.01741e-05
DCLRE1B
[NCBI]
1.01741e-05
HLA-C
[NCBI]
1.00247e-05
IL10
[NCBI]
9.99617e-06
CIZ1
[NCBI]
9.88685e-06
RPS27A
[NCBI]
9.42611e-06
CCT5
[NCBI]
9.42611e-06
TCP1
[NCBI]
8.90751e-06
RAD51L3
[NCBI]
8.51018e-06
IL21R
[NCBI]
8.51018e-06
TPT1
[NCBI]
8.51018e-06
HLA-DQA1
[NCBI]
8.44474e-06
ITPA
[NCBI]
8.09294e-06
GZMB
[NCBI]
8.05005e-06
PPP2CA
[NCBI]
7.75797e-06
AZGP1
[NCBI]
7.68359e-06
TBX21
[NCBI]
7.61233e-06
NEU1
[NCBI]
7.54393e-06
FIP1L1
[NCBI]
7.47818e-06
IFNGR1
[NCBI]
7.0779e-06
PTGER2
[NCBI]
7.02757e-06
DPEP1
[NCBI]
6.8853e-06
UBB
[NCBI]
6.79669e-06
TNF
[NCBI]
6.69309e-06
IFNGR2
[NCBI]
6.6719e-06
CYP2B6
[NCBI]
6.6719e-06
HLA-DRA
[NCBI]
6.63227e-06
CCL24
[NCBI]
6.59355e-06
MS4A2
[NCBI]
6.41222e-06
XRCC2
[NCBI]
6.18723e-06
HLA-DQB1
[NCBI]
6.03297e-06
ALOX5
[NCBI]
5.91046e-06
RNASE3
[NCBI]
5.74074e-06
MPO
[NCBI]
5.72902e-06
RYR1
[NCBI]
5.67297e-06
F9
[NCBI]
5.65097e-06
GSTP1
[NCBI]
5.46429e-06
HLA-DPB1
[NCBI]
5.22863e-06
EIF4EBP1
[NCBI]
4.86493e-06
CYP1A2
[NCBI]
4.79831e-06
ALOX5AP
[NCBI]
4.68483e-06
CD1D
[NCBI]
4.63682e-06
CAT
[NCBI]
4.59757e-06
PIP
[NCBI]
4.56734e-06
IL6
[NCBI]
4.36296e-06
AVP
[NCBI]
4.3327e-06
CCR4
[NCBI]
4.19435e-06
SHC1
[NCBI]
4.03186e-06
SOCS3
[NCBI]
4.00766e-06
CXCL10
[NCBI]
4.00766e-06
JAK1
[NCBI]
3.79089e-06
CCR3
[NCBI]
3.77008e-06
NPHS1
[NCBI]
3.58805e-06
CD46
[NCBI]
3.51025e-06
NQO1
[NCBI]
3.45859e-06
CTSG
[NCBI]
3.40315e-06
UGT1A1
[NCBI]
3.29792e-06
XRCC5
[NCBI]
3.23321e-06
MEFV
[NCBI]
3.22834e-06
GAPDH
[NCBI]
3.14333e-06
HNF1B
[NCBI]
3.12054e-06
EGR1
[NCBI]
3.08478e-06
PRKDC
[NCBI]
3.07598e-06
HLA-A
[NCBI]
3.04125e-06
HNF1A
[NCBI]
2.98236e-06
H2AFX
[NCBI]
2.97824e-06
ALB
[NCBI]
2.9257e-06
CCL11
[NCBI]
2.85214e-06
F8
[NCBI]
2.84836e-06
CYP3A4
[NCBI]
2.83337e-06
CCR5
[NCBI]
2.81853e-06
SLC2A1
[NCBI]
2.76419e-06
FAS
[NCBI]
2.75709e-06
FASLG
[NCBI]
2.75331e-06
FOXP3
[NCBI]
2.22583e-06
ESR1
[NCBI]
2.04041e-06
GSTT1
[NCBI]
2.00503e-06
CCL2
[NCBI]
1.97659e-06
GSTM1
[NCBI]
1.72751e-06
EGFR
[NCBI]
1.3106e-06
CD68
[NCBI]
1.08144e-06
AKT1
[NCBI]
8.56407e-07
TGFB1
[NCBI]
6.2511e-07
EPO
[NCBI]
5.1083e-07
VEGFA
[NCBI]
4.43836e-07
PRL
[NCBI]
3.7844e-07
PCNA
[NCBI]
3.59655e-07
OMIM
OMIM
Link
Information
gain
01
ocular myopathy with curare sensitivity
[NCBI]
0.00159179
asthma, nasal polyps, and aspirin intolerance
[NCBI]
0.000508161
HLA-B
[NCBI]
0.000422751
HSPA1L
[NCBI]
0.000236905
CPAF
[NCBI]
0.000163879
RNASE3
[NCBI]
0.000154515
mydriatic response to pharmacologic agents
[NCBI]
0.000118236
LTC4S
[NCBI]
9.92366e-05
craniosynostosis-microcephaly with chromosomal breakage and other abnormalities
[NCBI]
9.57739e-05
MHS1
[NCBI]
9.46851e-05
SLE
[NCBI]
9.00789e-05
EPHX1
[NCBI]
8.62119e-05
adie pupil
[NCBI]
8.18052e-05
bronchiectasis
[NCBI]
8.18052e-05
halothane hepatitis
[NCBI]
6.94508e-05
deafness, aminoglycoside-induced
[NCBI]
6.74301e-05
CIZ1
[NCBI]
6.49988e-05
DCLRE1B
[NCBI]
6.49988e-05
RPS27A
[NCBI]
6.49988e-05
severe cutaneous adverse reaction, susceptibility to
[NCBI]
6.25585e-05
DCLRE1A
[NCBI]
5.98009e-05
SCCMS
[NCBI]
5.58151e-05
ITPA
[NCBI]
5.39185e-05
PHF9
[NCBI]
5.19204e-05
TBX21
[NCBI]
5.19204e-05
GCE
[NCBI]
4.85962e-05
CF
[NCBI]
4.79103e-05
CYSLTR1
[NCBI]
4.75957e-05
CYP1A1
[NCBI]
4.70963e-05
ALOX5
[NCBI]
4.30113e-05
XRCC9
[NCBI]
4.10264e-05
BCPM
[NCBI]
4.02885e-05
HLA-A
[NCBI]
3.52958e-05
THPO
[NCBI]
3.46508e-05
STAT6
[NCBI]
3.0421e-05
RNASE2
[NCBI]
2.81066e-05
RYR1
[NCBI]
2.74944e-05
IL6
[NCBI]
2.13202e-05
leber optic atrophy
[NCBI]
1.93808e-05
MODY
[NCBI]
1.72794e-05
hla-d histocompatibility type
[NCBI]
1.63194e-05
CAT
[NCBI]
1.55858e-05
GAPDH
[NCBI]
1.24033e-05
ALB
[NCBI]
1.12878e-05
thrombocytopenic purpura, autoimmune
[NCBI]
9.67788e-06
AVP
[NCBI]
9.34413e-06
MPO
[NCBI]
6.05067e-06
FA
[NCBI]
5.29229e-06
TYMS
[NCBI]
5.07197e-06
G6PD
[NCBI]
3.74342e-06
CRC
[NCBI]
2.38572e-06
EGFR
[NCBI]
2.07836e-06
CRH
[NCBI]
1.67807e-06
TNF
[NCBI]
4.97671e-07
RA
[NCBI]
3.80521e-07
EPO
[NCBI]
1.74974e-07
MG
[NCBI]
3.21912e-08
PCNA
[NCBI]
7.10831e-09
PRL
[NCBI]
6.25105e-10
Database Center for Life Science